Ocular Oncology and Pathology最新文献

{"title":"Ethnic and Socioeconomic Factors Associated with Locally Advanced Retinoblastoma: A Retrospective Study.","authors":"Edward L Simpson, Benjamin A King, Linda A Cernichiaro-Espinosa, Carlos Rodriguez-Galindo, Chia-Wei Hsu, Pan Haitao, Matthew W Wilson","doi":"10.1159/000551496","DOIUrl":"10.1159/000551496","url":null,"abstract":"<p><strong>Introduction: </strong>Retinoblastoma provides an important opportunity to assess how racial and socioeconomic disparities in health care access may affect the timely diagnosis and treatment of a life-threatening disease.</p><p><strong>Methods: </strong>Patients with retinoblastoma treated at a single institution (1999-2021) were retrospectively reviewed with respect to race, Zone Improvement Plan (ZIP) code, and International Intraocular Retinoblastoma Classification (IIRC) Grouping. Socioeconomic disadvantage score (SDS) was assigned based on census data from each ZIP code. Logistic regression was performed, and odds ratio (OR) and 95% confidence intervals (CIs) were calculated using the generalized estimating equations (GEEs) logistic regression model (SAS, version 9.4) to analyze the probability of locally advanced retinoblastoma with respect to race and SDS. Advanced retinoblastoma was defined as IIRC Group E disease in at least one eye.</p><p><strong>Results: </strong>Of 445 patients, 189 presented with group E disease in at least one eye. Locally advanced retinoblastoma positively correlated with non-White race (OR = 1.38, 95% CI [1.03-1.85]). The SDS demonstrated a positive trend with advanced disease but did not reach statistical significance (OR = 3.03, 95% CI [0.25-36.27]). When accounting for age at presentation, neither race (OR = 1.13, 95% CI [0.74-1.72]) nor SDS (OR = 4.05, 95% CI [0.23-71.96]) were significantly associated with advanced retinoblastoma.</p><p><strong>Conclusions: </strong>A positive association was found between non-White race and Group E retinoblastoma, though this was not statistically significant after accounting for age at diagnosis. This emphasizes the importance of continuing education and outreach efforts to all patient communities to facilitate earlier diagnosis and ensure that care is delivered as equitably as possible.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"12 2","pages":"81-86"},"PeriodicalIF":1.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13216689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinal Capillary Hemangioblastoma: A Comprehensive Review on Treatments.","authors":"Masood Naseripour, Kaveh Fadakar, Fatemeh Azimi, Mohammad Mahdi Taherian, Mahya Naseripour, Reza Mirshahi","doi":"10.1159/000550011","DOIUrl":"10.1159/000550011","url":null,"abstract":"<p><strong>Background: </strong>Retinal capillary hemangioblastoma (RCH) is a benign tumor that frequently appears as the first manifestation in patients with von Hippel-Lindau (VHL) disease, potentially resulting in significant vision loss. Thus, recognizing and managing it promptly is crucial.</p><p><strong>Summary: </strong>New imaging techniques, including widefield optical coherence tomography (OCT) and OCT angiography, improve diagnostic accuracy and monitoring, facilitating early treatment and better prediction of visual outcomes. While traditional therapies such as laser photocoagulation, cryotherapy, and vascular endothelial growth factor inhibitors serve as the cornerstones of RCH therapy, new approaches, including tyrosine kinase inhibitors and hypoxia-inducible factor inhibitors, also exhibit promising results in treating resistant or recurrent tumors. Furthermore, genetic testing and counseling are beneficial for identifying patients linked to VHL disease, allowing early detection of systemic manifestations of this syndrome and enabling proper therapeutic management.</p><p><strong>Key messages: </strong>This review consolidates the epidemiology, pathophysiology, clinical imaging, diagnostic evaluation, and treatment of RCH, emphasizing new insights pertinent to clinical practice and patient care.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":" ","pages":"53-62"},"PeriodicalIF":1.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12846321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146093624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraocular Medulloepithelioma: A Rare but Important Mimicker of Retinoblastoma.","authors":"Genovefa Machairoudia, Anusha Venkataraman, Ulrike Löbel, Pritika Gaur, Victoria Bryant, Hannah Cottom, Catriona Duncan, Tanzina Chowdhury, Mandeep S Sagoo, M Ashwin Reddy, Guy S Negretti","doi":"10.1159/000549750","DOIUrl":"10.1159/000549750","url":null,"abstract":"<p><strong>Introduction: </strong>Medulloepithelioma is a rare tumour arising from the primitive medullary epithelium affecting predominantly children.</p><p><strong>Case presentations: </strong>We present 2 patients with ocular medulloepithelioma presenting in the first 2 years of life with strabismus, leukocoria and a large ocular mass occupying the globe. The clinical presentation and imaging initially raised suspicion for retinoblastoma and enucleation was performed. Histopathology confirmed the diagnosis of teratoid medulloepithelioma in both cases and genetic testing found a germline <i>DICER1</i> mutation in one of them.</p><p><strong>Conclusion: </strong>These cases highlight the importance of considering medulloepithelioma in the differential diagnosis of intraocular tumours and underscore the value of genetic evaluation for underlying <i>DICER1</i> mutations.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":" ","pages":"32-39"},"PeriodicalIF":1.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12782631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145952606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Virtual Clinics in Ocular Oncology.","authors":"Caoimhe Henry, Osman Younus, Manaim Shah, Julie Connolly, Paul Cauchi, Vikas Chadha","doi":"10.1159/000550302","DOIUrl":"10.1159/000550302","url":null,"abstract":"<p><strong>Background: </strong>Patients with treated uveal melanoma or suspicious choroidal naevi require a long period of follow-up to detect and treat malignant change in a timely manner. Ocular oncology patients are often managed in highly specialized services and such follow-up can create a significant burden on a service.</p><p><strong>Summary: </strong>The availability of high-quality imaging has increased acceptability of virtual clinics in other subspecialist areas of ophthalmology. Multi-modal imaging is an important tool for monitoring choroidal lesions and review of imaging by consultant ocular oncologist has been found to be highly sensitive and specific for detecting change of choroidal lesions. Virtual clinics can improve patient access to care, reducing barriers such as time, travel and financial costs. Our experience of virtual oncology clinics in the Scottish Ocular Oncology Service (SOOS) found a high level of patient satisfaction provided results are communicated to patients in a timely manner.</p><p><strong>Key messages: </strong>There is a need for increased capacity in both triaging and monitoring of choroidal naevomelanocytic lesions and virtual clinics provide an efficacious solution to this. Change in practice is challenging, however, with increased accessibility to high-quality imaging modalities, standardized assessment protocols, and focus on patient communication the role of virtual services in ocular oncology is promising.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":" ","pages":"63-68"},"PeriodicalIF":1.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12867511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146119810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinocytoma: Clinical and Genetic Characteristics in 16 Pediatric and Adult Cases.","authors":"Chloé Widehen, Nathalie Cassoux, Denis Malaise, Isabelle Aerts, François Doz, Marion Gauthier-Villars, Alexandre Matet, Livia Lumbroso-Le Rouic","doi":"10.1159/000548389","DOIUrl":"10.1159/000548389","url":null,"abstract":"<p><strong>Introduction: </strong>Retinocytomas are rare benign intraocular tumors that may mimic spontaneously regressed retinoblastoma (Rb).</p><p><strong>Materials and methods: </strong>This was a retrospective monocentric study of patients with retinocytoma in a French tertiary ocular oncology center, with an inclusion period from January 1999 to January 2024.</p><p><strong>Results: </strong>Sixteen patients with retinocytoma were identified, and 1,351 Rbs were diagnosed during the same 25-year period. Age at diagnosis ranged from 11 months to 75 years (mean 28.1 years). Thirteen cases were asymptomatic, while three presented with floaters, decreased visual acuity, or strabismus. Clinical presentation was a whitish or grayish retinal tumor with a translucent (87%) and/or fragmented appearance (76%) at diagnosis. A proportion of lesions were surrounded by atrophy (52%) and/or pigmentation (30%). Eleven patients had unilateral retinocytoma (one of which was multifocal), and five had bilateral lesions. Eight patients had a known family history of Rb. Patients were followed regularly and underwent genetic counseling. The eight patients with a family history had a germline pathogenic variation of the <i>RB1</i> gene. None showed malignant transformation during follow-up (mean 79.5 months, median 35.5 months).</p><p><strong>Conclusion: </strong>The presentation of retinocytoma is most often asymptomatic. Thus, diagnosis may be delayed to far later ages than expected with Rb. Retinocytoma may be associated with germline pathogenic variants of the <i>RB1</i> gene, and follow-up is recommended due to rare but possible malignant transformation.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"11 4","pages":"267-273"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145768761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Belzutifan for Ocular Tumors in Patients with von Hippel-Lindau Disease.","authors":"Farzad Jamshidi, Samuel Tadros, Lola Lozano, H Culver Boldt, Elaine Binkley","doi":"10.1159/000548701","DOIUrl":"10.1159/000548701","url":null,"abstract":"<p><strong>Background: </strong>Belzutifan is an orally administered small molecule inhibitor of HIF-2-alpha that has been approved for use in von Hippel-Lindau (VHL)-associated renal cell carcinoma, central nervous system (CNS) hemangioblastomas, and pancreatic neuro-endocrine tumors. While use of the drug for treatment of VHL-associated retinal hemangioblastomas (RH) remains off-label, numerous case reports, case series, and a clinical trial sub-analysis have demonstrated excellent results in using the drug to control these tumors.</p><p><strong>Summary: </strong>We review the literature that has been published on the use of belzutifan for RH in patients with VHL. These studies have described good efficacy for treating RH and preventing the development of new ocular tumors. The efficacy for juxtapapillary and macular tumors that can be difficult to treat has been particularly promising. Dose reductions are commonly required due to side effects which most commonly include anemia and fatigue.</p><p><strong>Key messages: </strong>While early reports are encouraging, the optimal dose of the drug for controlling RH along with the duration of therapy, role as a neoadjuvant, and ways to incorporate use of the drug into the treatment and screening paradigms for VHL-associated ocular disease are evolving.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"11 4","pages":"219-226"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145768817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uveal Melanomas Masquerading as Inflammatory Lesions.","authors":"Malcolm Wiseman, Timothy Fuller, R Nick Hogan, J William Harbour, Noy Ashkenazy","doi":"10.1159/000548277","DOIUrl":"10.1159/000548277","url":null,"abstract":"<p><strong>Introduction: </strong>Most uveal melanomas (UMs) are readily diagnosed based on their characteristic features, but they can occasionally pose a diagnostic challenge, such as when they present as an inflammatory mass. We present 2 patients who presented with an intraocular mass that was initially diagnosed as an inflammatory or infectious process and subsequently found to represent a UM.</p><p><strong>Case presentations: </strong>Two cases of UM masquerading as uveitis are described.</p><p><strong>Conclusion: </strong>UM should be considered in the differential diagnosis of an intraocular inflammatory mass. Diagnosis may require tumor biopsy.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":" ","pages":"248-251"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12582572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uveal Melanocytoma without GNAQ/GNA11 Mutations.","authors":"Seth T Kazmer, Rachel Frauches, Carlo Galang, Marinia Bishay, Don S Minckler, Prithvi Mruthyunjaya, Jonathan H Lin","doi":"10.1159/000549105","DOIUrl":"10.1159/000549105","url":null,"abstract":"<p><strong>Introduction: </strong>Uveal melanocytomas are benign melanocytic proliferations characterized histologically by large polyhedral cells, abundant intracytoplasmic melanin, small centrally located nuclei, and low nuclear-to-cytoplasmic ratios (N:C). Activating missense changes of the G-protein subunits, <i>GNAQ/GNA11</i>, drive uveal melanocytic proliferation and are characteristic molecular mutations found in intraocular nevi including melanocytomas, as well as malignant uveal melanomas. Sequencing of uveal melanocytic proliferations from biopsies or enucleations identifies these mutations and complements traditional histochemical approaches to classify and diagnose the uveal melanocytic neoplasm as well as offering valuable clinical prognoses about patient outcomes.</p><p><strong>Case presentation: </strong>A 56-year-old female presented with gradual, painless vision loss in the left eye. On exam, a large (11.1 × 12.8 × 10.6 mm by ocular ultrasound), hyperpigmented ciliochoroidal mass was found in the superior nasal quadrant abutting the lens. The patient elected for enucleation given the tumor's large size and vision loss in the affected eye. An fine needle aspiration (FNA) biopsy of the fresh mass, collected immediately after enucleation, revealed no mutations in the 7-gene DecisionDX-UMSeq panel. Histologic and immunohistochemical evaluation of pupil-optic nerve cross-sections from the formalin fixed paraffin embedded enucleation revealed a ciliary body melanocytoma. DNA extracted from the melanocytoma enucleation cross-sections was sequenced for 197-clinically actionable tumor genes through the Stanford's Actionable Mutation Panel for Solid Tumors (STAMP). The sequencing results confirmed no mutations in <i>GNAQ</i>, <i>GNA11</i>, and the other uveal melanoma genes tested via the DecisionDX-UMSeq panel but identified missense variants of unknown significance in three genes previously not reported in uveal melanocytic neoplasms.</p><p><strong>Conclusion: </strong>To our knowledge, this is the first reported uveal melanocytoma lacking <i>GNAQ/GNA11</i> oncogenic variants or other known uveal melanocytic neoplasm driver mutations. This case supports that there are additional to-be-identified molecular pathways and genes that drive uveal melanocyte proliferations.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"11 4","pages":"260-266"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145768764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary Choroidal Osteoma in the Setting of Uveal Pathology: 4 Case Reports and Review.","authors":"Minoru Furuta, Keiichiro Tanaka, Shunsuke Maeda, Ryo Mukai, Jerry A Shields, Carol L Shields, Tetsuju Sekiryu","doi":"10.1159/000548250","DOIUrl":"10.1159/000548250","url":null,"abstract":"<p><strong>Introduction: </strong>Choroidal osteoma is a rare benign tumor where mature bone replaces the choroid. Possible causes include inflammation, trauma, hormones, disorders of calcium metabolism, environmental factors, genetics, or osseous choristoma. This paper discusses 4 cases and literature regarding choroidal osteoma occurring concurrently with or secondary to uveal pathologies including uveitis and pachychoroid spectrum.</p><p><strong>Case presentations: </strong>In case 1, a 41-year-old man with central serous chorioretinopathy (CSCR) in both eyes (OU) developed a choroidal osteoma in the left eye (OS) 8 years after the initial visit. Type 1 macular neovascularization (MNV) developed 4 years later at age 53. In case 2, a 50-year-old woman with CSCR OU developed a choroidal osteoma OS 15 years after the initial visit. The lesion gradually enlarged over another 15 years of observation. In case 3, a 24-year-old woman with Vogt-Koyanagi-Harada disease treated with systemic corticosteroids for 6 months developed choroidal osteoma OU and type 2 MNV in the right eye (OD) 16 years after the initial visit. In case 4, a 55-year-old man with concurrent posterior scleritis and choroidal osteoma OS developed type 1 MNV 13 years after the initial visit. He had a history of unknown uveitis treated with high-dose corticosteroid therapy 21 years previously. In all 5 eyes, the presence of osseous tissue in the choriocapillaris and Sattler's layer was confirmed by optical coherence tomography, B-mode ultrasound, or computed tomography. These lesions demonstrated observed growth in basal diameter and/or maturation process of bone tissue throughout the follow-up period.</p><p><strong>Conclusion: </strong>We observed 5 eyes of four patients with choroidal osteoma in the choriocapillaris and Sattler's layer of the choroid secondary to CSCR, Vogt-Koyanagi-Harada disease, or posterior scleritis over a long follow-up period of 12-30 years. Secondary choroidal osteoma, ectopic bone in the choroid, can result from the transformation of mesenchymal cells stimulated by osteoprogenitors, such as bone morphogenetic proteins. Secondary choroidal osteoma should be recognized as a rare long-term complication of uveal pathologies.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":" ","pages":"237-247"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound Biomicroscopy in the Diagnosis and Management of Iris and Ciliary Body Tumors: A Comprehensive Review.","authors":"Dibya Prabha, Arun D Singh, Vishal Raval","doi":"10.1159/000549104","DOIUrl":"10.1159/000549104","url":null,"abstract":"<p><strong>Background: </strong>Although uncommon, tumors of the iris and ciliary body present significant diagnostic challenges because of their variable appearance and overlap between benign and malignant features and the difficulty of directly visualizing lesions located in the posterior iris or ciliary body using conventional methods.</p><p><strong>Summary: </strong>The advent of high-resolution anterior segment imaging, particularly ultrasound biomicroscopy (UBM), has greatly enhanced the ability of clinicians to evaluate these lesions in vivo. This review synthesizes current evidence on the utility of UBM in the diagnosis, classification, and management of both iris and ciliary body tumors. The emphasis is placed on differentiating melanotic from amelanotic lesions, recognizing imaging characteristics that suggest malignancy and comparing UBM with other anterior segment modalities, such as gonioscopy and anterior segment optical coherence tomography. This study provides a detailed discussion of tumor morphology, growth patterns, and secondary complications, supplemented by illustrative examples from clinical practice.</p><p><strong>Key message: </strong>UBM serves as a noninvasive, reproducible, and dynamic view of lesions located deep within the anterior segment, particularly those obscured from direct examination, thereby guiding both diagnosis and longitudinal management.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"11 4","pages":"227-236"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145768769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}